← All companies
Psychedelic drug developers
Definium Therapeutics
Nasdaq: DFTX · formerly MindMed · New York, NY · Website
$32.08
−2.79% (−$0.92) on the day
Close Nov 13, 2026
Market cap
$4.39B
1 month
−6.36%
52-week range
$10.46–$49.70
Last month
Why we cover it
Formerly MindMed, renamed in January 2026. Its lead drug, DT120, is LSD delivered as a tablet that dissolves in the mouth, in Phase 3 for generalized anxiety disorder and depression. Both of its anxiety Phase 3 trials have been positive.
Financials
| Cash & equivalents | $241M | as of Sep 30, 2026 · 10-Q |
| Research & development | $46.1M | quarter ended Sep 30, 2026 · 10-Q |
| Net income (loss) | −$51.0M | quarter ended Sep 30, 2026 · 10-Q |
From the company's SEC filings. See all filings ↗
Clinical trials Trials tracker
| Trial | Compound | Stage |
|---|---|---|
| DT120 for Generalized Anxiety Disorder and Depression | LSD | Phase 3 (two of two GAD trials positive) |
News (8)
- Nov 9, 2026 Definium Now Has $1 Billion and a 2027 Filing Date for Its LSD Pill. It Still Isn't Saying Which Disorder Goes First.
- Nov 6, 2026 What We're Watching: Compass's Filing Clock, Definium's First Call Since Its Rally, and the Ibogaine Deadline
- Sep 28, 2026 Definium's LSD Pill Already Won a Phase 3 in Depression — Not Just Anxiety
- Sep 17, 2026 Definition Day: DT120
- Sep 16, 2026 Definium's LSD Compound Just Posted Its Second Positive Phase 3 Trial for Anxiety
- Sep 2, 2026 Definition Day: 5-HT2A Receptor & Microdosing
- Aug 26, 2026 New on Altitude: LSD Has 14 Patents in Our Tracker. The Company Closest to Approval Owns One.
- Aug 12, 2026 MindMed Renamed Itself Definium — And Its LSD Trial Just Posted Positive Phase 3 Results
In the Journal (15)
- Nov 12, 2026 How Long Does Relief Last? Antidepressants vs. Psychedelics, by the Numbers
- Nov 11, 2026 Altitude People Series, Week 3 — Business: The Billionaire Who Built a Psychedelics Company on One Mushroom Trip
- Nov 7, 2026 After the Election, the Fights Move Indoors: ICER, a Courtroom and a New Drug Law for Psilocybin
- Oct 1, 2026 Meet the 7 People Who Actually Lobby for Psychedelics in Washington
- Sep 29, 2026 Only 3 of 10 Psychedelic Companies Lobby Washington. One Just Joined — Twice, in the Same Quarter.
- Sep 26, 2026 150+ Patents, $113 Million Raised, 4 Employees: Inside the Company Betting It Doesn't Need to Run Its Own Trials
- Sep 26, 2026 The "Nibble It" Problem: What Your Doctor Doesn't Have to Tell You About Off-Label Prescriptions
- Sep 23, 2026 Which Psychedelic-Company CEO's Pay Actually Matched Their Stock's Performance? We Checked All 10 — Almost None Did.
- Sep 22, 2026 How Clinical Trials Actually Work — and What It Means for the Psychedelic Industry
- Sep 22, 2026 Nausea for 12 Hours vs. Sexual Dysfunction for Years: The Side-Effect Math Nobody's Doing on Mental Health Drugs
- Sep 21, 2026 19% of American Adults Have Anxiety. Every Drug Treating It Is a Decades-Old Generic — Here's Who Wins If DT120 Changes That
- Sep 17, 2026 The Psychedelic Money Graveyard: Renames, Reverse Mergers, and the Companies That Didn't Make It
Prices are end-of-day closes from Nasdaq; financials come from SEC filings. Not investment advice.